FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530276238> ?p ?o ?g. }

• W2530276238 abstract "Abstract Abstract 612 Recent work has shown that acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients exhibit downregulation of miR-146a, a miRNA that negatively regulates the innate immune pathway by targeting IRAK1 and TRAF6. Mice lacking miR-146a show elevated IRAK1 protein expression, and develop AML and MDS-like features resembling the human diseases. Prior to this study, the role of IRAK1 in human myeloid malignancies was unknown. We conducted a comparison of gene expression profiles of 136 cases of MDS CD34+ cells with 17 normal CD34+ cells obtained from ArrayExpress (E-GEOD-19429; Pellagatti et al., Leukemia, 2010). According to this data set, we observed IRAK1 overexpression in MDS patients (P = 0.017). IRAK1 is a serine/threonine kinase, and after phosphorylation on threonine-209 (T209), its kinase activity is induced, thus allowing for subsequent activation of TRAF6 and eventually NF-kB. Interestingly, we observed higher basal levels of phospho-IRAK1 at T209 in MDS and AML samples as compared to normal human CD34+ cells. To investigate the potential role of IRAK1 in AML and MDS, we used genetic and pharmacological approaches to suppress IRAK1 activity in MDS/AML cell lines and bone marrow cells from MDS patients. RNAi-mediated knockdown of IRAK1 in MDS and AML samples resulted in impaired growth of malignant hematopoietic stem/progenitor cells in methylcellulose assays and rapid apoptosis in vitro. In addition, we used a small-molecule inhibitor (benzimidazole analog; Amgen Inc.) to potently inhibit IRAK1 kinase activity. MDS/AML cell lines and MDS patient samples cultured with the IRAK1 inhibitor exhibited impaired growth and increased apoptosis, which coincided with decreased phospho-IRAK1 at T209, and active versions of TRAF6 and NF-kB. Importantly, the inhibition of IRAK1 kinase function is selectively detrimental to MDS and AML samples while preserving normal CD34+ cell viability and function. Given this novel requirement of IRAK1 in MDS and AML, we examined whether Lenalidomide or Bortezomib, two treatment options for MDS/AML and reported immunosuppressors, exhibit anti-leukemic activity in part by targeting IRAK1. We observed that Bortezomib, but not Lenalidomide, inhibits IRAK1 mRNA and protein expression in MDS/AML cells. The cytotoxic effect of Bortezomib can be partly rescued by forced expression of IRAK1 in these cells. To determine the molecular and cellular basis of cell death following loss of IRAK1 function or expression, we applied microarrays to MDS cells treated with IRAK1 inhibitor or transduced with a lentiviral vector encoding an shRNA targeting IRAK1. An overlap of commonly deregulated genes imposed by loss of IRAK1 expression or by the IRAK1 inhibitor revealed unique pathways relevant to the survival of MDS and AML cells. In summary, these findings are the first to implicate IRAK1 in the maintenance of myeloid malignancies and describe the effectiveness of an IRAK1 inhibitor on suppressing MDS and AML viability. Disclosures: Oliva: Celgene: Consultancy." @default.
• W2530276238 created "2016-10-21" @default.
• W2530276238 creator A5000522683 @default.
• W2530276238 creator A5009827973 @default.
• W2530276238 creator A5033305440 @default.
• W2530276238 creator A5037735415 @default.
• W2530276238 creator A5041711274 @default.
• W2530276238 creator A5056930112 @default.
• W2530276238 creator A5068661721 @default.
• W2530276238 creator A5070924011 @default.
• W2530276238 date "2011-11-18" @default.
• W2530276238 modified "2023-09-27" @default.
• W2530276238 title "Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome" @default.
• W2530276238 doi "https://doi.org/10.1182/blood.v118.21.612.612" @default.
• W2530276238 hasPublicationYear "2011" @default.
• W2530276238 type Work @default.
• W2530276238 sameAs 2530276238 @default.
• W2530276238 citedByCount "2" @default.
• W2530276238 countsByYear W25302762382012 @default.
• W2530276238 countsByYear W25302762382020 @default.
• W2530276238 crossrefType "journal-article" @default.
• W2530276238 hasAuthorship W2530276238A5000522683 @default.
• W2530276238 hasAuthorship W2530276238A5009827973 @default.
• W2530276238 hasAuthorship W2530276238A5033305440 @default.
• W2530276238 hasAuthorship W2530276238A5037735415 @default.
• W2530276238 hasAuthorship W2530276238A5041711274 @default.
• W2530276238 hasAuthorship W2530276238A5056930112 @default.
• W2530276238 hasAuthorship W2530276238A5068661721 @default.
• W2530276238 hasAuthorship W2530276238A5070924011 @default.
• W2530276238 hasConcept C10205521 @default.
• W2530276238 hasConcept C109159458 @default.
• W2530276238 hasConcept C173396325 @default.
• W2530276238 hasConcept C190283241 @default.
• W2530276238 hasConcept C201750760 @default.
• W2530276238 hasConcept C203014093 @default.
• W2530276238 hasConcept C2778461978 @default.
• W2530276238 hasConcept C2778729363 @default.
• W2530276238 hasConcept C2779282312 @default.
• W2530276238 hasConcept C2780007613 @default.
• W2530276238 hasConcept C2780817109 @default.
• W2530276238 hasConcept C28328180 @default.
• W2530276238 hasConcept C502942594 @default.
• W2530276238 hasConcept C54355233 @default.
• W2530276238 hasConcept C71924100 @default.
• W2530276238 hasConcept C86803240 @default.
• W2530276238 hasConcept C95444343 @default.
• W2530276238 hasConceptScore W2530276238C10205521 @default.
• W2530276238 hasConceptScore W2530276238C109159458 @default.
• W2530276238 hasConceptScore W2530276238C173396325 @default.
• W2530276238 hasConceptScore W2530276238C190283241 @default.
• W2530276238 hasConceptScore W2530276238C201750760 @default.
• W2530276238 hasConceptScore W2530276238C203014093 @default.
• W2530276238 hasConceptScore W2530276238C2778461978 @default.
• W2530276238 hasConceptScore W2530276238C2778729363 @default.
• W2530276238 hasConceptScore W2530276238C2779282312 @default.
• W2530276238 hasConceptScore W2530276238C2780007613 @default.
• W2530276238 hasConceptScore W2530276238C2780817109 @default.
• W2530276238 hasConceptScore W2530276238C28328180 @default.
• W2530276238 hasConceptScore W2530276238C502942594 @default.
• W2530276238 hasConceptScore W2530276238C54355233 @default.
• W2530276238 hasConceptScore W2530276238C71924100 @default.
• W2530276238 hasConceptScore W2530276238C86803240 @default.
• W2530276238 hasConceptScore W2530276238C95444343 @default.
• W2530276238 hasLocation W25302762381 @default.
• W2530276238 hasOpenAccess W2530276238 @default.
• W2530276238 hasPrimaryLocation W25302762381 @default.
• W2530276238 hasRelatedWork W1480336412 @default.
• W2530276238 hasRelatedWork W2029329948 @default.
• W2530276238 hasRelatedWork W2048715803 @default.
• W2530276238 hasRelatedWork W2414800588 @default.
• W2530276238 hasRelatedWork W2549930601 @default.
• W2530276238 hasRelatedWork W2551034811 @default.
• W2530276238 hasRelatedWork W2566628926 @default.
• W2530276238 hasRelatedWork W2590890078 @default.
• W2530276238 hasRelatedWork W2606219893 @default.
• W2530276238 hasRelatedWork W2741014649 @default.
• W2530276238 hasRelatedWork W2746022227 @default.
• W2530276238 hasRelatedWork W2786434754 @default.
• W2530276238 hasRelatedWork W2794827287 @default.
• W2530276238 hasRelatedWork W2893478266 @default.
• W2530276238 hasRelatedWork W2895922378 @default.
• W2530276238 hasRelatedWork W2980034193 @default.
• W2530276238 hasRelatedWork W2980275429 @default.
• W2530276238 hasRelatedWork W3161975265 @default.
• W2530276238 hasRelatedWork W3203806696 @default.
• W2530276238 hasRelatedWork W842833586 @default.
• W2530276238 isParatext "false" @default.
• W2530276238 isRetracted "false" @default.
• W2530276238 magId "2530276238" @default.
• W2530276238 workType "article" @default.